The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.

Anouk K M ClaessensReinier TimmanJan J BusschbachJeanette M BoumaJeany M Rademaker-LakhaiFrans L G ErdkampVivianne C G Tjan-HeijnenMonique E M M Bosnull null

Published in: Breast cancer research and treatment (2019)

Intermittent first- and second-line chemotherapy in patients with HER2-negative advanced breast cancer showed a trend for worse impact on QoL compared to continuous chemotherapy, with neither significant nor meaningful differences in course. We recommend prescribing chemotherapy continuously until progressive disease or unacceptable toxicity. Trial registration EudraCT 2010-021519-18; BOOG 2010-02.

Keyphrases

locally advanced
primary care
multiple sclerosis
clinical trial
high intensity
squamous cell carcinoma
rectal cancer
emergency department
oxidative stress
chemotherapy induced
phase iii
young adults